JP7282736B2 - カプサイシンを使用した疼痛の治療のための方法及び組成物 - Google Patents

カプサイシンを使用した疼痛の治療のための方法及び組成物 Download PDF

Info

Publication number
JP7282736B2
JP7282736B2 JP2020502343A JP2020502343A JP7282736B2 JP 7282736 B2 JP7282736 B2 JP 7282736B2 JP 2020502343 A JP2020502343 A JP 2020502343A JP 2020502343 A JP2020502343 A JP 2020502343A JP 7282736 B2 JP7282736 B2 JP 7282736B2
Authority
JP
Japan
Prior art keywords
joint
certain embodiments
patient
skin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527574A5 (cg-RX-API-DMAC7.html
JP2020527574A (ja
Inventor
ジェイムズ・エヌ・キャンベル
ピーター・ディ・ハンソン
ゲイリー・エフ・ムッソ
ドレイゼン・オストビック
ランドール・スティーブンズ
Original Assignee
セントレクシオン セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントレクシオン セラピューティクス コーポレイション filed Critical セントレクシオン セラピューティクス コーポレイション
Publication of JP2020527574A publication Critical patent/JP2020527574A/ja
Publication of JP2020527574A5 publication Critical patent/JP2020527574A5/ja
Priority to JP2023081213A priority Critical patent/JP7738031B2/ja
Application granted granted Critical
Publication of JP7282736B2 publication Critical patent/JP7282736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/10—Cooling bags, e.g. ice-bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001—Body part
    • A61F2007/0039—Leg or parts thereof
    • A61F2007/0042—Knee

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Thermal Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
JP2020502343A 2017-07-20 2018-07-20 カプサイシンを使用した疼痛の治療のための方法及び組成物 Active JP7282736B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081213A JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535003P 2017-07-20 2017-07-20
US62/535,003 2017-07-20
PCT/US2018/043094 WO2019018769A1 (en) 2017-07-20 2018-07-20 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081213A Division JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2020527574A JP2020527574A (ja) 2020-09-10
JP2020527574A5 JP2020527574A5 (cg-RX-API-DMAC7.html) 2021-08-26
JP7282736B2 true JP7282736B2 (ja) 2023-05-29

Family

ID=65016186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502343A Active JP7282736B2 (ja) 2017-07-20 2018-07-20 カプサイシンを使用した疼痛の治療のための方法及び組成物
JP2023081213A Active JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081213A Active JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Country Status (11)

Country Link
US (4) US20200206166A1 (cg-RX-API-DMAC7.html)
EP (1) EP3654961B1 (cg-RX-API-DMAC7.html)
JP (2) JP7282736B2 (cg-RX-API-DMAC7.html)
CN (1) CN111201015A (cg-RX-API-DMAC7.html)
AU (1) AU2018302342B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020000989A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069540A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018268T3 (cg-RX-API-DMAC7.html)
IL (1) IL272036B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020000488A (cg-RX-API-DMAC7.html)
WO (1) WO2019018769A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023116457A (ja) * 2017-07-20 2023-08-22 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3840739B1 (en) * 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
CN114028540B (zh) * 2021-11-26 2023-10-17 海南鑫开源医药科技有限公司 一种具有镇痛作用的组合物、微针贴片及其制备方法以及应用
CN115006379B (zh) * 2021-12-28 2023-12-15 南京清普生物科技有限公司 一种trpv1激动剂原位膜剂组合物,及其制备方法和用途
US12233115B2 (en) * 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536998A (ja) 2012-11-12 2015-12-24 エイピーアイ・ジェネシス,エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法
JP2016540830A (ja) 2013-11-12 2016-12-28 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 水性カプサイシノイド配合物ならびに製造法および使用法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5431914A (en) 1992-04-17 1995-07-11 Adekunle; Michael Method of treating an internal condition by external application of capsaicin without the need for systemic absorption
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
DE59408028D1 (de) 1993-09-30 1999-05-06 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
WO1998020867A1 (en) 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
US6060060A (en) 1997-01-31 2000-05-09 Bmb Patent Holding Corporation Analgesic compositions from sweet peppers and methods of use thereof
EP1201241B8 (en) 1997-03-13 2010-10-27 James N. Campbell Compositions containing capsaicin or capsaicin analogues and an anesthetic
JP2002514221A (ja) 1997-05-27 2002-05-14 アルゴス ファーマシューティカル コーポレーション カプサイシノイド及びその強化薬を含有する鎮痛薬組成物
CA2442049C (en) 2001-03-22 2010-06-01 Michael J. Iadarola Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
WO2004009064A1 (de) 2002-07-19 2004-01-29 Mestex Ag Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
NZ540769A (en) 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
WO2004056305A2 (en) 2002-12-18 2004-07-08 Algorx Administration of capsaicinoids
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
WO2006066419A1 (de) 2004-12-22 2006-06-29 Mestex Ag Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
EP1838301B1 (de) 2004-12-28 2015-01-28 Mestex AG Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen
ES2384244T3 (es) 2004-12-28 2012-07-02 Mestex Ag Utilización de un agonista del receptor vaniloide juntamente con un glicosaminoglicano o un proteoglicano para la fabricación de un fármaco para el tratamiento de los dolores articulares y procedimiento para la aplicación de este fármaco
WO2006105481A1 (en) * 2005-03-30 2006-10-05 Neurogesx, Inc. Low-concentration capsaicin patch and methods for treating neuropathic pain
US20080160487A1 (en) 2006-12-29 2008-07-03 Fairfield Language Technologies Modularized computer-aided language learning method and system
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
CN101507818B (zh) 2008-12-15 2010-11-10 中国人民武装警察部队医学院 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
ES2821490T3 (es) * 2010-03-30 2021-04-26 The Childrens Res Institute Aparato y método de algometría humana
KR101769010B1 (ko) * 2011-09-09 2017-08-17 비쭈리 헬스 사이언스 엘엘씨 Trpv1 선택적 작용제를 포함하는 통증 완화 조성물, 및 이의 제조방법 및 용도
US9566187B2 (en) 2012-03-13 2017-02-14 Breg, Inc. Cold therapy systems and methods
WO2013158814A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
EP2838536B1 (en) 2012-04-18 2017-08-09 Mallinckrodt LLC Immediate release pharmaceutical compositions with abuse deterrent properties
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US20150190509A1 (en) 2012-08-03 2015-07-09 Mestex Ag Resiniferatoxin solution
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
ES2838756T3 (es) 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
MX2016013486A (es) 2014-04-14 2017-05-10 Flex Pharma Inc Activadores de canales ionicos y metodos de uso.
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
US10736842B2 (en) 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
EP3182968A4 (en) 2014-08-19 2018-05-09 Muzari, Mandishora Israel Capsaicinoids and uses thereof as medicaments
US20180311189A1 (en) 2014-11-13 2018-11-01 Centrexion Therapeutics Corporation Capsaicinoids for Use in Treating ACRAL Lick Granuloma
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US20180021286A1 (en) 2015-02-02 2018-01-25 Enspire Group LLC Stabilized dialkyl fumarate compositions
CA2987517A1 (en) 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
US20200261409A1 (en) 2015-11-20 2020-08-20 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
US20190022036A1 (en) 2016-01-22 2019-01-24 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of morton's neuroma pain
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA3025268A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2018217937A1 (en) 2017-05-24 2018-11-29 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2019018769A1 (en) * 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536998A (ja) 2012-11-12 2015-12-24 エイピーアイ・ジェネシス,エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法
JP2016540830A (ja) 2013-11-12 2016-12-28 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 水性カプサイシノイド配合物ならびに製造法および使用法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Neurophysiology,1991年, 66(1),pp.190-211

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023116457A (ja) * 2017-07-20 2023-08-22 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物
JP7738031B2 (ja) 2017-07-20 2025-09-11 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物

Also Published As

Publication number Publication date
US20250312298A1 (en) 2025-10-09
JP2023116457A (ja) 2023-08-22
US20200206166A1 (en) 2020-07-02
EP3654961B1 (en) 2025-01-08
JP7738031B2 (ja) 2025-09-11
EP3654961C0 (en) 2025-01-08
IL272036B2 (en) 2025-01-01
WO2019018769A1 (en) 2019-01-24
US11026903B2 (en) 2021-06-08
ES3018268T3 (en) 2025-05-14
US12201594B2 (en) 2025-01-21
EP3654961A4 (en) 2021-04-21
AU2018302342B2 (en) 2024-08-08
IL272036B1 (en) 2024-09-01
JP2020527574A (ja) 2020-09-10
AU2018302342A1 (en) 2020-02-06
US20210299072A1 (en) 2021-09-30
MX2020000488A (es) 2020-10-28
CN111201015A (zh) 2020-05-26
CA3069540A1 (en) 2019-01-24
IL272036A (en) 2020-03-31
US20200360314A1 (en) 2020-11-19
EP3654961A1 (en) 2020-05-27
BR112020000989A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
JP7738031B2 (ja) カプサイシンを使用した疼痛の治療のための方法及び組成物
JP6474732B2 (ja) 激痛治療用組成物と方法
CN104968368A (zh) 固溶体组合物及其在剧痛中的用途
Daneshkazemi et al. The efficacy of eutectic mixture of local anesthetics as a topical anesthetic agent used for dental procedures: A brief review
US20140142073A1 (en) Aqueous based capsaicinoid formulations and methods of manufacture and use
JP7100635B2 (ja) 安定な水性カプサイシン注射製剤およびその医学的使用
JP2012528193A (ja) 局所脂肪組織の処置のための投与方法および処方物
CN108697673A (zh) 用于治疗莫顿神经瘤疼痛的辣椒碱依次给予方法
Webster et al. Review of intra‐articular local anaesthetic administration in horses: Clinical indications, cytotoxicity, and outcomes
US20250241879A1 (en) Capsaicin sequential dosing method for treatment of knee joint pain
US20100190860A1 (en) Methods for selectively enhancing antinociceptive potency of local anesthetics
HK40031064B (en) Compositions and their use for treatment of pain using capsaicin
HK40031064A (en) Compositions and their use for treatment of pain using capsaicin
Wong et al. Comparison of the Effect of Two Different Doses of 0.75% Glucose‐Free Ropivacaine for Spinal Anesthesia for Lower Limb and Lower Abdominal Surgery
Jin et al. Effects of Low-Dose Dexamethasone Regimens on Early Clinical Outcomes After Unicompartmental Knee Arthroplasty: A Retrospective Cohort Study
Mallika et al. ROLE OF DEXMEDETOMIDINE AND CLONIDINE AS ADJUVANTS WITH ROPIVACAINE IN EPIDURAL ANAESTHESIA-A COMPARATIVE STUDY
Hassan et al. Pharmacodynamic evaluation of dexmedetomidine as an additive drug to bupivacaine in ultrasound-guided interscalene brachial plexus block.
Mosimann et al. Usefulness of intra-articular bupivacain and lidocain adjunction in MR or CT arthrography: A prospective study in 148 patients
Shehab et al. Therapeutic efficacy of a preoperative epidural single shot of dexamethasone/levobupivacaine for postoperative analgesia (a placebo-controlled comparative study against epidural neostigmine/levobupivacaine)
Gritsenko et al. Postoperative Blocks That Afford Long-Lasting Pain Relief

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230517

R150 Certificate of patent or registration of utility model

Ref document number: 7282736

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250